VEGFER-2 INHIBITORS AND QUINAZOLINE-BASED ANTICANCER AGENTS
Al-Azhar Journal of Pharmaceutical Sciences · 01.09.2023 · 68 (2) · 111-129
DOI: 10.21608/ajps.2023.332170 ↗Kurz gefasst
Fachartikel in der Zeitschrift Al-Azhar Journal of Pharmaceutical Sciences, online erschienen am 01.09.2023. Verfasst von Helmy Sakr und 3 weiteren Autor:innen. Die Arbeit wurde bisher 7-mal zitiert (Crossref).
Abstract (Originalsprache)
Inhibitors of vascular endothelial growth factor receptor -2 (VEGFR-2) are crucial biological targets for the development of novel anticancer medications. Quinazoline also plays an important role as one of the building elements of numerous anticancer drugs. Thus, a review of the literature on VEGFR-2 inhibitors and Quinazoline-based anticancer medicines has been completed. We introduced VEGFR-2 inhibitors now undergoing clinical evaluation, such as Gefitinib, Erlotinib, Vandetanib, Afatinib, Lenvatinib, Cabozantinib, Sorafenib and Regorafenib in our survey. Additionally, VEGFR-2 inhibitors that are under development were introduced.
Zitieren
APA
Sakr, H., Otify, I., Ayyad, R., & Elwan, A. (2023). VEGFER-2 INHIBITORS AND QUINAZOLINE-BASED ANTICANCER AGENTS. Al-Azhar Journal of Pharmaceutical Sciences, 68(2), 111-129. https://doi.org/10.21608/ajps.2023.332170
Vancouver
Sakr H, Otify I, Ayyad R, Elwan A. VEGFER-2 INHIBITORS AND QUINAZOLINE-BASED ANTICANCER AGENTS. Al-Azhar Journal of Pharmaceutical Sciences. 2023;68(2):111-129. doi:10.21608/ajps.2023.332170
BibTeX
@article{Sakr2023,
author = {Sakr, Helmy and Otify, Islam and Ayyad, Rezk and Elwan, Alaa},
title = {VEGFER-2 INHIBITORS AND QUINAZOLINE-BASED ANTICANCER AGENTS},
journal = {Al-Azhar Journal of Pharmaceutical Sciences},
year = {2023},
volume = {68},
number = {2},
pages = {111--129},
doi = {10.21608/ajps.2023.332170}
}
EUVIMED